Filing Flows › Agios Pharmaceuticals (AGIO) › Q3 2026
Agios Pharmaceuticals (AGIO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 5, 2026
Agios Pharmaceuticals (AGIO) reported revenue of $55.4M for the third quarter 2026 (Q3 2026), +330% from a year earlier and +24% from the quarter before. Operating margin was -139.3%, net loss $65.0M (117.4% of revenue).
Agios Pharmaceuticals, Q3 2026: revenue $55.4M (+330% year over year), operating margin -139.3%, net loss $65.0M, operating cash flow −$59.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $55.4M | +24% | +330% |
| Operating profit | −$77.2M | — | — |
| Net earnings | −$65.0M | — | — |
| Operating cash flow | −$59.2M | — | — |
What changed
Revenue was $55.4M in Q3 2026, up 330% year over year and up 24% from the previous quarter.
Operating costs exceeded revenue by $77.2M, an operating margin of -139.3%. Total costs grew 2% against revenue growth of 330%. The fastest-growing cost line was Cost of revenue (+50%). The quarter ended with a net loss of $65.0M, narrower than the previous quarter's $100.7M loss.
Operating cash flow was −$59.2M. Non-cash charges added back $16.7M of share-based compensation. Working capital and other items used $10.9M. Capital expenditures of $1.2M exceeded it, leaving free cash flow of −$60.4M.
Questions
What was Agios Pharmaceuticals' revenue in the third quarter 2026?
Agios Pharmaceuticals (AGIO) reported revenue of $55.4M for the third quarter 2026 (Q3 2026), +330% from a year earlier and +24% from the quarter before.
Was Agios Pharmaceuticals profitable in the third quarter 2026?
Operating loss was $77.2M (-139.3% of revenue) and net loss $65.0M.